Mechanism of B cell maturaion
Mechanism of B cell maturaion
批准号:
07457089
负责人:
TAKEMORI Toshitada
金额:
$1.47万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996
中文摘要
点击翻译按钮获取中文摘要
英文摘要
A/WySnJ mouse. a subline of A/J,is known to be deficient in B cell maturation. We observed in the present study that formation of the primary follicle in the spleen is deficient in A/WySnJ mouse, as compared to A/J,which could be associated with deficiency in signal cascade including MAPK/ERK in the B cells, resulting in poor response to CD40 and IgM stimulation in vitro.CD40 stimulation is essential for B cell activation and differentiation, such as class-switch, germinal center formation, and generation of memory. We observed in the present study that cd40 stimulation resulted in activation of MAPK/ERK via Ras-Raf-1-MEK signal pathway. The cytoplasmic tail of CD40 associates with TRAF2, TRAF3, TRAF5, and TRAF6. These TRAF proteins with exception for TRAF3 play a role in NF_KB activation in CD40 signaling. Our biochemical study showed that TRAF3 could inhibit MAPK/ERK activation in CD40 signaling. As overexpression of TRAF3 is known to suppress function of other TRAF proteins, the result is compatible with the idea that the TRAF protein as yet to be defined plays a role in MAPK/ERK activation in CD40 signaling.After activation, B cells enter into the primary follicles and establish germinal center. We observed that, in contrast to well-developed germinal center, Ig+ germinal center B cells are mostly in cell cycling. There cells expand and occupy germinal center at high frequency on day 7-8 after immunization ; however, these cycling B cells rapidly reduced the number on day 8-10 postimmunization.During that time these cells accumulate somatic hypermutation and could be selected by antigen. Rapidly cycling Ig+ germinal center B cells have potent antigen-presenting activity in vitro, suggesting that somatic hypermutation and antigen selection may operate simultaneously, probable via activation through T-cell interaction.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Kimoto,H.,Nagaoka,H.,Adachi,Y.,Yagi,T.,Azuma,T.,Sata,T.,Yonehara,S.,Tsunetsugu-Yokota,Y.,Taniguchi,M.and Takemori,T.: "Accumulation of somatic hypermutation and antigen-driven selection in rapidly cycling surface Ig+ germinal center (GC) B cells which occ
木本 H.、长冈 H.、足立 Y.、八木 T.、东 T.、佐田 T.、米原 S.、横田恒次 Y.、谷口 M. 和竹森 T
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Misawa,Y.,Nagaoka,H.,Kimoto,H.,Kobayashi,M.,Shibuya,M.,and Takemori,T.: "CD43 expression in a B cell lymphoma,WEHI 231,reduces susceptibility to G1 arrest and extends survival in culture upon serum depletion." Eur.J.Immunol.26. 2573-2581 (1996)
Misawa,Y.、Nagaoka,H.、Kimoto,H.、Kobayashi,M.、Shibuya,M. 和 Takemori,T.:“B 细胞淋巴瘤中的 CD43 表达,WEHI 231,降低了对 G1 停滞的敏感性并延长了
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hagiwara,S.,Tsunetsugu-Yokota,Y.,Kimoto,H.and Takemori,T.: "Expression of VpreB3(8HS-20)molecules by alternative RNA processing." Int.Immunol.8. 1237-1244 (1996)
Hagiwara,S.、Tsunetsugu-Yokota,Y.、Kimoto,H. 和 Takemori,T.:“通过替代 RNA 处理表达 VpreB3(8HS-20) 分子。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Hagiwara,S.,Tsunetsugu-Yokota,Y.,Kimoto,H.and Takemori,T.: "Expression of VpreB3 (8HS-20) molecules by alternative RNA processing." Int.Immunol.8. 1237-1244 (1996)
Hagiwara,S.、Tsunetsugu-Yokota,Y.、Kimoto,H. 和 Takemori,T.:“通过替代 RNA 加工表达 VpreB3 (8HS-20) 分子。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Kashiwada,M.,Kaneko,Y.,Yagita,H.,Okumura,K.and Takemori,T.: "Activation of mitogen-activated protein kinases via CD40 is distinct from that stimulated by surface IgM on B cells." Eur.J.Immunol.26. 1451-1458 (1996)
Kashiwada,M.、Kaneko,Y.、Yagita,H.、Okumura,K. 和 Takemori,T.:“通过 CD40 激活有丝分裂原激活的蛋白激酶与 B 细胞表面 IgM 刺激的激活不同。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 7 条
Memory B cell commitment, maintenance and terminal differentiation
-
批准号:16043261
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$25.34万
-
财政年份:2004
-
负责人:TAKEMORI Toshitada
-
依托单位:
Molecular mechanism for memory B cell dynamics and survival
-
批准号:15390164
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.6万
-
财政年份:2003
-
负责人:TAKEMORI Toshitada
-
依托单位:
Molecular events in the generation of memory B cells.
-
批准号:13470076
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.61万
-
财政年份:2001
-
负责人:TAKEMORI Toshitada
-
依托单位:
The analysis of B cell differentiation and maturation
-
批准号:02454196
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$3.97万
-
财政年份:1990
-
负责人:TAKEMORI Toshitada
-
依托单位:
Analysis of lymphoid cell differentiation
-
批准号:63480166
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.74万
-
财政年份:1988
-
负责人:TAKEMORI Toshitada
-
依托单位:
国内基金
海外基金
登录
查看更多内容
EB病毒蛋白BZLF1上调CD40/CD40L-
KU80/RAG信号通路促进BCR二次重排在机
体丧失自身免疫耐受的机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:侯显良
-
依托单位:
CD40激动剂介导巨噬细胞M1极化激活放疗旁观者效应的研究
-
批准号:JCZRYB202500454
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
基于CD40/TAMS探究益气活血解毒方纳米囊泡诱导卵巢癌富脂微环境冷热转化免疫增效机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:卢雯平
-
依托单位:
基于前列腺癌类器官模型的B7H3靶向ADC药物与CD40协同免疫治疗研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:王晓婷
-
依托单位:
CD40/CD40L通路激活CD8+毒性T淋巴细胞调控TED眼眶组织重塑的机制研究
-
批准号:82371105
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:谭佳
-
依托单位:
锰增敏的CD40免疫检查点调控对植入物感染免疫治疗的效应和机制研究
-
批准号:82302717
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:杨闯
-
依托单位:
大弹涂鱼CD40作为MOSPD2共受体调控LEAP2趋化单核巨噬细胞的分子机制
-
批准号:LZ23C190001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:陈炯
-
依托单位:
荷载糖皮质激素和CD40核酸适配体的水凝胶微针用于治疗甲状腺相关性眼病的疗效和机制研究
-
批准号:2023JJ30851
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:熊炜
-
依托单位:
CREBBP/P300调控CD40介导Tfh-B细胞纠缠在肾移植ABMR中的机制研究
-
批准号:LQ23H050004
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:郭陆英
-
依托单位:
工程化外泌体表达CD40调控B细胞活性在系统性红斑狼疮治疗中的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:梁欣
-
依托单位: